Ashleigh Kernohan

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Replacement Therapy

Early Breast Cancer

Epidermal Growth Factor Receptor

Top Venues

The British journal of ophthalmology

PharmacoEconomics

Systematic reviews

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Hossein Shabaninejad, Tara Homer, Ashleigh Kernohan, Anthony J King, Jennifer M Burr, Augusto Azuara-Blanco, Luke Vale
Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. The British journal of ophthalmology 108 (9) (2024)
Hossein Shabaninejad, Tara Homer, Ashleigh Kernohan, Anthony J King, Jennifer M Burr, Augusto Azuara-Blanco, Luke Vale
Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. The British journal of ophthalmology 108 (9) (2024)
Hossein Shabaninejad, Tara Homer, Ashleigh Kernohan, Anthony J King, Jennifer M Burr, Augusto Azuara-Blanco, Luke Vale
Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. The British journal of ophthalmology 108 (9) (2024)
Hossein Shabaninejad, Tara Homer, Ashleigh Kernohan, Anthony J King, Jennifer M Burr, Augusto Azuara-Blanco, Luke Vale
Is primary trabeculectomy cost-effective for patients with advanced primary open angle glaucoma? Results from the Treatment of Advanced Glaucoma Study economic model. The British journal of ophthalmology (2024)
Giovany Orozco-Leal, Nigel Armstrong, Ashleigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin T McDermott, Steven Duffy, Susan O'Meara, Tomos Robinson, Luke Vale, Jos Kleijnen
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2023)
Diarmuid Coughlan, Oluwatomi Arisa, Katie H Thomson, Ge Yu, Fiona Pearson, Ashleigh Kernohan, Sonia Garcia Gonzalez-Moral, Sheila A Wallace, Stephen Rice
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective. PharmacoEconomics (2023)
Ashleigh Kernohan, Tomos Robinson, Luke Vale
Incorporating economic methods into Cochrane systematic reviews: case studies in brain tumour research. Systematic reviews 12 (1) (2023)
Giovany Orozco-Leal, Nigel Armstrong, Ashleigh Kernohan, Charlotte Ahmadu, Diarmuid Coughlan, Kevin T McDermott, Steven Duffy, Susan O'Meara, Tomos Robinson, Luke Vale, Jos Kleijnen
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2023)
Ashleigh Kernohan, Tara Homer, Hosein Shabaninejad, Anthony J King, Jemma Hudson, Gordon Fernie, Augusto Azuara-Blanco, Jennifer M Burr, John M Sparrow, David Garway-Heath, Keith Barton, John Norrie, Graeme Maclennan, Luke Vale
Cost-effectiveness of primary surgical versus primary medical management in the treatment of patients presenting with advanced glaucoma. The British journal of ophthalmology (2022)
Anthony J King, Gordon Fernie, Jemma Hudson, Ashleigh Kernohan, Augusto Azuara-Blanco, Jennifer M Burr, Tara Homer, Hossein Shabaninejad, John M Sparrow, David F Garway-Heath, Keith Barton, John Dt Norrie, Alison M McDonald, Luke Vale, Graeme Maclennan
Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT. Health technology assessment (Winchester, England) 25 (72) (2022)